A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kadmon Corporation, LLC
• Treatments: Metformin

Criteria

Inclusion Criteria:

• HbA1c 7-11%

• On a stable dose of metformin for at least 6 weeks

Exclusion Criteria:

• Type 1 Diabetes

• Antidiabetic medication other than or in addition to metformin

• FPG > 270 mg/dL